FDA Calendar, Unbiased Reporting on Emerging Biotech Sector Now Available at BioMedReports.com

PITTSBURGH--(EON: Enhanced Online News)--BioMedReports.com, designed by and for investors and traders, is a full news portal offering unbiased bio stock reporting and analysis about emerging biotech companies, FDA and clinical trial calendars, and valuable industry and stock market information.

“Investors are hungry for clarity and no-hype reporting. I’m one of them”

“Investors are hungry for clarity and no-hype reporting. I’m one of them,” said M.E. Garza, co-founder of BioMedReports.com. “BioMedReports was born out of necessity. As an active investor, I quickly figured out that investors might benefit financially if armed with knowledge of upcoming FDA approvals, so I went looking for it.”

Garza’s research showed companies were charging exorbitant prices for FDA and clinical trials calendars, and much of it wasn’t even up to date. Then he found Mike Havrilla, an index developer and blogger, who focuses on the fast-growing healthcare sector. Havrilla’s extremely popular blog had more free information and clinical trial updates than the more expensive members-only sites. The two partnered to build a full news portal that serves both institutional and penny-stock bio investors. Even before the official launch, visitors and subscribers started finding BioMedReports.com online.

“That’s when we knew we were on to something. Biotechnology, in the eyes of many experts, could become the next bubble in the stock market. Even during the recession, many of these stocks have had tremendous gains. Some of the most incredible biomedical breakthroughs are coming from companies who are currently trading for pennies a share,” Garza said.

Havrilla, who has a B.S. (Biology) and PharmD, has incredible bio industry knowledge and a very unique perspective, which won him thousands of followers on his original blog, now archived at http://biomedreports.com/blog.html.

BioMedReports.com offers free and premium subscription options, with a $120 annual fee for access to more than 200 entries for pending FDA decisions, clinical trial results, and pending re-submissions or new filings for FDA approval. The monthly cost of $10 compares to an average online stock trading commission. Competing report sites charge $125 per month or more for their research.

“No one else anywhere compiles or provides this information," Havrilla said. “And they certainly won’t give it to you at the BioMedReports price, which is one-twentieth the cost of similar monthly reports. And, users have dynamic data access to the calendars, rather than a static PDF report.”

The BioMedReports.com FDA Calendar includes companies with pending new drug, biological agent or medical device decisions by the FDA – updated daily (106 entries as of 3/25/09) as new information becomes available.
Subscribers also get the BioMedReports exclusive Clinical Trial Calendar (137 entries as of 3/25/09), which encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials).
Free features include front page news and commentaries, blog entries, stock research reports, and a database of more than 1,000 healthcare stocks and organized indexes.
BioMedReports.com even has stock profile reports available – including a new report for adult stem cell and regenerative medicine leader Cytori Therapeutics (NASDAQ:CYTX).

About BioMedReports.com

BioMedReports.com is a website for healthcare investors and traders, which features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries and other unique content – including FDA and clinical trial calendars, plus a database that includes nearly 1,000 stocks and exchange-traded funds.